Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio
Eliminating the risk of polio from vaccine-derived polioviruses is essential for creating a polio-free world, and eliminating that risk will require stopping use of all oral polio vaccines (OPVs) once all types of wild polioviruses have been eradicated. In many ways, the experience with the global s...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2017-07, Vol.216 (suppl_1), p.S217-S225 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S225 |
|---|---|
| container_issue | suppl_1 |
| container_start_page | S217 |
| container_title | The Journal of infectious diseases |
| container_volume | 216 |
| creator | Hampton, Lee M. du Châtellier, Gaël Maufras Fournier-Caruana, Jacqueline Ottosen, Ann Rubin, Jennifer Menning, Lisa Farrell, Margaret Shendale, Stephanie Patel, Manish |
| description | Eliminating the risk of polio from vaccine-derived polioviruses is essential for creating a polio-free world, and eliminating that risk will require stopping use of all oral polio vaccines (OPVs) once all types of wild polioviruses have been eradicated. In many ways, the experience with the global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) can inform the eventual full global withdrawal of OPV. Significant preparation will be needed for a thorough, synchronized, and full withdrawal of OPV, and such preparation would be aided by setting a reasonably firm date for OPV withdrawal as far in advance as possible, ideally at least 24 months. A shorter lead time would provide valuable flexibility for decisions about when to stop use of OPV in the context of uncertainty about whether or not all types of wild polioviruses had been eradicated, but it might increase the cost of OPV withdrawal. |
| doi_str_mv | 10.1093/infdis/jix105 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5853572</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26365478</jstor_id><oup_id>10.1093/infdis/jix105</oup_id><sourcerecordid>26365478</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-337cdccf8abde06080e8808ae7cd899350d307d016971a016b23c3569f0c0f393</originalsourceid><addsrcrecordid>eNqFkUtP3DAUha2qqAy0yy5beckmcJ2bOM4GCY14SUiw6GNXy-NHx6NMPLUTHv8eQ3iUFatzZX869-geQr4y2GfQ4oHvnfHpYOVvGdQfyIzV2BScM_xIZgBlWTDRtttkJ6UVAFTIm09kuxQCBWtxRv7MQ5-8sVENPk_UhUiHpaUnY9fR0y4sVEd_-2FporrJY3D0Mma9Cp0P9JfS2veWHrnBRnoclfH60eeBe0Q-ky2numS_POku-Xly_GN-Vlxcnp7Pjy4KXVXlUCA22mjthFoYCxwEWCFAKJufc3yswSA0BhhvG6ayLErUWPPWgQaHLe6Sw8l3My7W1mjbDzmm3ES_VvFOBuXl25_eL-XfcC1rUWPdlNlg78kghn-jTYNc-6Rt16nehjHJfKxSVFC2PKPFhOoYUorWvaxhIB86kVMncuok89__z_ZCP5fwujuMm3e9vk3oKg0hvlpx5HXVCLwHJq-iUg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932840296</pqid></control><display><type>article</type><title>Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Hampton, Lee M. ; du Châtellier, Gaël Maufras ; Fournier-Caruana, Jacqueline ; Ottosen, Ann ; Rubin, Jennifer ; Menning, Lisa ; Farrell, Margaret ; Shendale, Stephanie ; Patel, Manish</creator><creatorcontrib>Hampton, Lee M. ; du Châtellier, Gaël Maufras ; Fournier-Caruana, Jacqueline ; Ottosen, Ann ; Rubin, Jennifer ; Menning, Lisa ; Farrell, Margaret ; Shendale, Stephanie ; Patel, Manish</creatorcontrib><description>Eliminating the risk of polio from vaccine-derived polioviruses is essential for creating a polio-free world, and eliminating that risk will require stopping use of all oral polio vaccines (OPVs) once all types of wild polioviruses have been eradicated. In many ways, the experience with the global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) can inform the eventual full global withdrawal of OPV. Significant preparation will be needed for a thorough, synchronized, and full withdrawal of OPV, and such preparation would be aided by setting a reasonably firm date for OPV withdrawal as far in advance as possible, ideally at least 24 months. A shorter lead time would provide valuable flexibility for decisions about when to stop use of OPV in the context of uncertainty about whether or not all types of wild polioviruses had been eradicated, but it might increase the cost of OPV withdrawal.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jix105</identifier><identifier>PMID: 28838193</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Disease Eradication ; Disease Outbreaks - prevention & control ; Global Health ; Humans ; IPV INTRODUCTION AND THE SWITCH ; Poliomyelitis - prevention & control ; Poliomyelitis - transmission ; Poliomyelitis - virology ; Poliovirus Vaccine, Oral ; Supplement</subject><ispartof>The Journal of infectious diseases, 2017-07, Vol.216 (suppl_1), p.S217-S225</ispartof><rights>Copyright © 2016 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. 2017</rights><rights>The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-337cdccf8abde06080e8808ae7cd899350d307d016971a016b23c3569f0c0f393</citedby><cites>FETCH-LOGICAL-c442t-337cdccf8abde06080e8808ae7cd899350d307d016971a016b23c3569f0c0f393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26365478$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26365478$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,799,881,1578,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28838193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hampton, Lee M.</creatorcontrib><creatorcontrib>du Châtellier, Gaël Maufras</creatorcontrib><creatorcontrib>Fournier-Caruana, Jacqueline</creatorcontrib><creatorcontrib>Ottosen, Ann</creatorcontrib><creatorcontrib>Rubin, Jennifer</creatorcontrib><creatorcontrib>Menning, Lisa</creatorcontrib><creatorcontrib>Farrell, Margaret</creatorcontrib><creatorcontrib>Shendale, Stephanie</creatorcontrib><creatorcontrib>Patel, Manish</creatorcontrib><title>Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Eliminating the risk of polio from vaccine-derived polioviruses is essential for creating a polio-free world, and eliminating that risk will require stopping use of all oral polio vaccines (OPVs) once all types of wild polioviruses have been eradicated. In many ways, the experience with the global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) can inform the eventual full global withdrawal of OPV. Significant preparation will be needed for a thorough, synchronized, and full withdrawal of OPV, and such preparation would be aided by setting a reasonably firm date for OPV withdrawal as far in advance as possible, ideally at least 24 months. A shorter lead time would provide valuable flexibility for decisions about when to stop use of OPV in the context of uncertainty about whether or not all types of wild polioviruses had been eradicated, but it might increase the cost of OPV withdrawal.</description><subject>Disease Eradication</subject><subject>Disease Outbreaks - prevention & control</subject><subject>Global Health</subject><subject>Humans</subject><subject>IPV INTRODUCTION AND THE SWITCH</subject><subject>Poliomyelitis - prevention & control</subject><subject>Poliomyelitis - transmission</subject><subject>Poliomyelitis - virology</subject><subject>Poliovirus Vaccine, Oral</subject><subject>Supplement</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqFkUtP3DAUha2qqAy0yy5beckmcJ2bOM4GCY14SUiw6GNXy-NHx6NMPLUTHv8eQ3iUFatzZX869-geQr4y2GfQ4oHvnfHpYOVvGdQfyIzV2BScM_xIZgBlWTDRtttkJ6UVAFTIm09kuxQCBWtxRv7MQ5-8sVENPk_UhUiHpaUnY9fR0y4sVEd_-2FporrJY3D0Mma9Cp0P9JfS2veWHrnBRnoclfH60eeBe0Q-ky2numS_POku-Xly_GN-Vlxcnp7Pjy4KXVXlUCA22mjthFoYCxwEWCFAKJufc3yswSA0BhhvG6ayLErUWPPWgQaHLe6Sw8l3My7W1mjbDzmm3ES_VvFOBuXl25_eL-XfcC1rUWPdlNlg78kghn-jTYNc-6Rt16nehjHJfKxSVFC2PKPFhOoYUorWvaxhIB86kVMncuok89__z_ZCP5fwujuMm3e9vk3oKg0hvlpx5HXVCLwHJq-iUg</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Hampton, Lee M.</creator><creator>du Châtellier, Gaël Maufras</creator><creator>Fournier-Caruana, Jacqueline</creator><creator>Ottosen, Ann</creator><creator>Rubin, Jennifer</creator><creator>Menning, Lisa</creator><creator>Farrell, Margaret</creator><creator>Shendale, Stephanie</creator><creator>Patel, Manish</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170701</creationdate><title>Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio</title><author>Hampton, Lee M. ; du Châtellier, Gaël Maufras ; Fournier-Caruana, Jacqueline ; Ottosen, Ann ; Rubin, Jennifer ; Menning, Lisa ; Farrell, Margaret ; Shendale, Stephanie ; Patel, Manish</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-337cdccf8abde06080e8808ae7cd899350d307d016971a016b23c3569f0c0f393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Disease Eradication</topic><topic>Disease Outbreaks - prevention & control</topic><topic>Global Health</topic><topic>Humans</topic><topic>IPV INTRODUCTION AND THE SWITCH</topic><topic>Poliomyelitis - prevention & control</topic><topic>Poliomyelitis - transmission</topic><topic>Poliomyelitis - virology</topic><topic>Poliovirus Vaccine, Oral</topic><topic>Supplement</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hampton, Lee M.</creatorcontrib><creatorcontrib>du Châtellier, Gaël Maufras</creatorcontrib><creatorcontrib>Fournier-Caruana, Jacqueline</creatorcontrib><creatorcontrib>Ottosen, Ann</creatorcontrib><creatorcontrib>Rubin, Jennifer</creatorcontrib><creatorcontrib>Menning, Lisa</creatorcontrib><creatorcontrib>Farrell, Margaret</creatorcontrib><creatorcontrib>Shendale, Stephanie</creatorcontrib><creatorcontrib>Patel, Manish</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hampton, Lee M.</au><au>du Châtellier, Gaël Maufras</au><au>Fournier-Caruana, Jacqueline</au><au>Ottosen, Ann</au><au>Rubin, Jennifer</au><au>Menning, Lisa</au><au>Farrell, Margaret</au><au>Shendale, Stephanie</au><au>Patel, Manish</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>216</volume><issue>suppl_1</issue><spage>S217</spage><epage>S225</epage><pages>S217-S225</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Eliminating the risk of polio from vaccine-derived polioviruses is essential for creating a polio-free world, and eliminating that risk will require stopping use of all oral polio vaccines (OPVs) once all types of wild polioviruses have been eradicated. In many ways, the experience with the global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) can inform the eventual full global withdrawal of OPV. Significant preparation will be needed for a thorough, synchronized, and full withdrawal of OPV, and such preparation would be aided by setting a reasonably firm date for OPV withdrawal as far in advance as possible, ideally at least 24 months. A shorter lead time would provide valuable flexibility for decisions about when to stop use of OPV in the context of uncertainty about whether or not all types of wild polioviruses had been eradicated, but it might increase the cost of OPV withdrawal.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>28838193</pmid><doi>10.1093/infdis/jix105</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2017-07, Vol.216 (suppl_1), p.S217-S225 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5853572 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Disease Eradication Disease Outbreaks - prevention & control Global Health Humans IPV INTRODUCTION AND THE SWITCH Poliomyelitis - prevention & control Poliomyelitis - transmission Poliomyelitis - virology Poliovirus Vaccine, Oral Supplement |
| title | Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T20%3A27%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Considerations%20for%20the%20Full%20Global%20Withdrawal%20of%20Oral%20Polio%20Vaccine%20After%20Eradication%20of%20Polio&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Hampton,%20Lee%20M.&rft.date=2017-07-01&rft.volume=216&rft.issue=suppl_1&rft.spage=S217&rft.epage=S225&rft.pages=S217-S225&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jix105&rft_dat=%3Cjstor_pubme%3E26365478%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932840296&rft_id=info:pmid/28838193&rft_jstor_id=26365478&rft_oup_id=10.1093/infdis/jix105&rfr_iscdi=true |